RGCC (Research Genetics Cancer Center)

RGCC International, also known as Research Genetic Cancer Centre, is a privately held biotechnology and diagnostics company founded in 2004 by Dr. Ioannis Papasotiriou. Based in Zug, Switzerland, the company focuses on personalized cancer diagnostics, molecular genetics, and laboratory research. Its work is built around analyzing cancer-related cellular and genetic characteristics to generate information that may help qualified healthcare professionals evaluate individual patient cases.

RGCC offers a range of laboratory testing services, including circulating tumor cell analysis, molecular profiling, genetic testing, and other cellular and biomarker investigations. Its research activities span cancer biology, molecular analysis, assay development, flow cytometry, and immunology. The company also publishes scientific research and collaborates with healthcare practitioners and research partners to advance laboratory methods and precision-oncology approaches.

Through its international network, RGCC works with clinicians, laboratories, and healthcare professionals seeking specialized diagnostic information for individualized patient assessment. Its leadership includes founder and director Dr. Ioannis Papasotiriou, alongside laboratory and research professionals such as Dr. Stefan Rubner and Panagiotis Apostolou. The company’s broader focus is on connecting laboratory research with clinical decision-making while continuing to develop technologies in cancer diagnostics and molecular medicine. Test results should be interpreted by qualified clinicians and considered alongside established diagnostic methods and the patient’s overall clinical picture.